Home › Liposarcoma
Pag-aaral pangklinika para sa Liposarcoma na nagre-recruit sa U.S.
17 pag-aaral para sa Liposarcoma ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX10 pag-aaral
- Boston, MA7 pag-aaral
- St. Louis, MO5 pag-aaral
- Chicago, IL5 pag-aaral
- New York City, NY5 pag-aaral
- Queens, NY5 pag-aaral
- Edison, NJ4 pag-aaral
- Atlanta, GA4 pag-aaral
- Seattle, WA3 pag-aaral
- Phoenix, AZ3 pag-aaral
- Richmond, VA3 pag-aaral
- Tampa, FL3 pag-aaral
- Nashville, TN3 pag-aaral
- San Diego, CA3 pag-aaral
- Miami, FL3 pag-aaral
- Gainesville, FL3 pag-aaral
- Louisville, KY3 pag-aaral
- Pittsburgh, PA3 pag-aaral
- Aurora, CO3 pag-aaral
- New Rochelle, NY3 pag-aaral
- Greenburgh, NY3 pag-aaral
- Columbus, OH3 pag-aaral
- Rochester, MN3 pag-aaral
Ayos sa estado
- Arizona3 pag-aaral
- California6 pag-aaral
- Colorado3 pag-aaral
- Connecticut3 pag-aaral
- Florida4 pag-aaral
- Georgia4 pag-aaral
- Illinois5 pag-aaral
- Kentucky3 pag-aaral
- Massachusetts7 pag-aaral
- Michigan4 pag-aaral
- Minnesota3 pag-aaral
- Missouri5 pag-aaral
- New Jersey5 pag-aaral
- New York6 pag-aaral
- Ohio6 pag-aaral
- Pennsylvania4 pag-aaral
- Tennessee4 pag-aaral
- Texas11 pag-aaral
- Virginia5 pag-aaral
- Washington3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06498648A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06881992Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06422806A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06025747A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06843967Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04031677Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06578624Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT05711615Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06541262STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06975293Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT04715191NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06239272A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07089992Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 15, 2026 · NCT07377747A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT06789172Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Nagre-recruitPhase 1
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update Nob 3, 2025 · NCT06198296Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.